Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma

Vascular endothelial growth factor (VEGF) levels in both the aqueous and vitreous are elevated in ocular ischemia secondary to exudative age-related macular degeneration, diabetes mellitus, and other retinal vascular diseases.1,2 Retinal ischemia upregulates VEGF production resulting in neovascularization of the retina and the iris (NVI). VEGF is significantly elevated in neovascular glaucoma (NVG).3 In the following case series, we demonstrate elevated aqueous VEGF levels in two patients with NVI that significantly declined with concurrent resolution of NVI following off-label intracameral injections of bevacizumab.